Carbazole: A Versatile Scaffold in Medicinal Chemistry – A Review on the Synthesis and Antimicrobial Evaluation of New Derivatives
Prem Kumar1*, Reneesh Jaiswal2, Rajesh Meshram3, Sudhish Rai4
1,2,3School of Pharmacy, Chouksey Engineering College Bilaspur, Chhattisgarh, India.
4Jagrani Devi Pharmacy College, Baradwar, Shakti, Chhattisgarh, India.
*Corresponding Author E-mail: yprem173@gmail.com
ABSTRACT:
The relentless rise of antimicrobial resistance (AMR) poses a grave threat to global public health, necessitating the urgent discovery of novel therapeutic agents with new mechanisms of action. Nitrogen-containing heterocycles have long been recognized as privileged structures in drug discovery due to their diverse biological activities. Among them, the carbazole nucleus, a tricyclic aromatic system comprising two benzene rings fused on either side of a pyrrole ring, has emerged as a highly promising scaffold. Carbazole derivatives are widely distributed in nature and have demonstrated a broad spectrum of pharmacological properties, including significant antimicrobial activity. This review systematically consolidates and critically evaluates the recent advancements (from approximately 2015 to the present) in the design, synthesis, and antimicrobial evaluation of new carbazole-based derivatives. We delve into various synthetic strategies, ranging from classical methods like the Bischler-Napieralski and Graebe-Ullmann reactions to modern transition-metal-catalyzed approaches for constructing the carbazole core and its functionalized analogues. A major focus is placed on the structure-activity relationship (SAR) studies, elucidating how different substituents—such as halogens, nitro groups, amino groups, and various heterocyclic hybrids—influence the potency and spectrum of activity against a panel of pathogenic bacteria and fungi. The review also discusses the potential mechanisms of action, including DNA intercalation, inhibition of efflux pumps, and disruption of microbial cell membranes. Finally, we address the current challenges and future perspectives for developing carbazole derivatives as a new class of clinically viable antimicrobial agents to combat the escalating AMR crisis.
The golden era of antibiotics is waning. The World Health Organization (WHO) has declared antimicrobial resistance (AMR) one of the top ten global public health threats facing humanity1. The overuse and misuse of existing antibiotics have led to the emergence of multidrug-resistant (MDR) strains of bacteria (e.g., MRSA, VRE, and carbapenem-resistant Enterobacteriaceae) and fungi (e.g., Candida auris), rendering many conventional treatments ineffective2. This alarming situation underscores the critical and immediate need for new antimicrobial chemotypes with novel mechanisms of action to bypass existing resistance pathways.
In the quest for new bioactive molecules, heterocyclic compounds have played a pivotal role. Carbazole, a tricyclic system (C12H9N) composed of two benzene rings fused to a central pyrrole ring, represents a "privileged scaffold" in medicinal chemistry. Its planar, aromatic, and relatively rigid structure allows for efficient interaction with various biological targets, such as enzymes and DNA3. Naturally occurring carbazole alkaloids, isolated from sources like coal tar and plants of the Rutaceae family, have been used for centuries in traditional medicine, hinting at their intrinsic biological potential4.
The intrinsic bioactivity of the carbazole core can be significantly enhanced and fine-tuned through chemical modification. Introducing diverse functional groups at various positions (1- to 4- and 9-) of the carbazole ring system can dramatically alter its electronic properties, lipophilicity, and hydrogen-bonding capacity, thereby modulating its interaction with microbial targets5. This review aims to provide a comprehensive overview of the recent literature on the synthesis of new carbazole derivatives and their evaluation as antimicrobial agents, with a particular emphasis on deciphering the structure-activity relationships that govern their efficacy.
Synthesis of Carbazole Derivatives:
The synthesis of the carbazole core and its derivatives can be achieved through both classical and modern synthetic methodologies.
Classical Synthetic Routes:
1. Graebe-Ullmann Reaction: This is one of the oldest methods, involving the thermal decomposition of 1-phenylbenzotriazoles to yield carbazoles. While useful, it often requires high temperatures and may have limited substrate scope6.
2. Bischler-Napieralski Reaction: This cyclization is employed for the synthesis of dihydrocarbazolones, which can be subsequently dehydrogenated to carbazoles. It is particularly useful for generating carbazoles fused with other ring systems7.
3. Sulfur-Assisted Cyclization (Cadogan-Sundberg Reaction): This method involves the cyclization of 2-nitrobiaryls using trialkyl phosphites, providing a direct route to the carbazole skeleton8.
Modern Transition-Metal-Catalyzed Syntheses:
Modern synthetic chemistry has provided more efficient and versatile tools for carbazole synthesis.
1. Palladium-Catalyzed Reactions: Palladium catalysis is the cornerstone of modern carbazole chemistry.
Buchwald-Hartwig Amination: Intramolecular C-N coupling of 2-amino-biaryls is a highly reliable and widely used method for constructing the carbazole ring9.
Suzuki-Miyaura and Other Cross-Couplings: These reactions are indispensable for introducing diverse aryl and heteroaryl substituents at specific positions of a pre-formed carbazole core, allowing for rapid SAR exploration [10].
2. Gold and Rhodium Catalysis: These metals have been successfully employed in redox-neutral and oxidative cyclizations of tailored substrates, such as diarylaminodienynes or biaryl hydrazones, to afford functionalized carbazoles under mild conditions11.
Antimicrobial Evaluation of Carbazole Derivatives:
A wide array of carbazole derivatives has been synthesized and screened for their antimicrobial potential. The primary in vitro evaluation involves determining the Minimum Inhibitory Concentration (MIC) against Gram-positive bacteria (e.g., Staphylococcus aureus, Bacillus subtilis), Gram-negative bacteria (e.g., Escherichia coli, Pseudomonas aeruginosa), and fungal strains (e.g., Candida albicans, Aspergillus niger).
Antibacterial Activity:
1. Simple Substituted Carbazoles: Early studies focused on introducing simple electron-withdrawing or electron-donating groups. For instance, 3,6-dibromocarbazole and 3,6-dinitrocarbazole have shown potent activity against Gram-positive bacteria, with MIC values as low as 3.12 µg/mL, often surpassing standard drugs like ampicillin12. The nitro group's strong electron-withdrawing effect is believed to enhance interaction with bacterial enzymes.
2. Aminoalkyl and Arylaminocarbazoles: Derivatives bearing aminoalkyl side chains, particularly at the N-9 position, have demonstrated broad-spectrum activity. The protonatable nitrogen in the side chain is thought to facilitate penetration through the bacterial cell membrane. A study by Patil et al. showed that 9-(2-(diethylamino) ethyl) carbazole was effective against both S. aureus and E. coli13.
3. Hybrid Molecules: This is a highly successful strategy where the carbazole unit is conjugated with other pharmacophores known for antimicrobial activity.
Carbazole-Triazole Hybrids: The 1,2,3-triazole ring, capable of hydrogen bonding and dipole interactions, is a common choice. These hybrids have shown remarkable activity against drug-resistant strains like MRSA14.
Carbazole-Quinoline/Quinolone Hybrids: Combining carbazole with the quinoline scaffold (a classic antimalarial and antibacterial core) has yielded compounds with dual potential, showing potent inhibition of DNA gyrase, a key bacterial enzyme15.
Carbazole-Chalcone Hybrids: Chalcones are known for their wide biological activities. Hybrids featuring a chalcone moiety linked to the carbazole core have exhibited significant antibacterial and antibiofilm activity16.
Antifungal Activity:
The antifungal potential of carbazoles is equally promising. Derivatives with halogen substituents (Cl, Br) at the 3- and 6- positions have consistently shown good activity against Candida species. The mechanism is often linked to the disruption of the fungal cell membrane, leading to leakage of cellular contents. For example, a series of 3,6-dichloro-9H-carbazole-1,4-diones demonstrated potent activity against C. albicans with an MIC of 6.25 µg/mL, comparable to fluconazole17. Hybrid molecules, especially those incorporating azole moieties (e.g., imidazole), mimic the structure of common antifungal drugs and can inhibit ergosterol biosynthesis by targeting lanosterol 14α-demethylase.
Structure-Activity Relationship (SAR) Analysis
A critical analysis of the literature reveals several key SAR trends:
Structure: Carbazole
Role of the Carbazole Core: The planar, lipophilic core is essential for intercalating into DNA or stacking with enzyme active sites. Any modification that disrupts planarity often reduces activity.
Influence of Substituents:
Position: Substitution at the 3- and 6- positions is generally more favorable for activity than at the 1- and 8- positions. The N-9 position is a key site for introducing side chains that modulate physicochemical properties.
Electron-Withdrawing Groups (EWGs): NO2, CN, and halogens (Cl, Br, F) at the 3- and/or 6- positions significantly enhance antibacterial activity, likely by increasing electron affinity and facilitating interaction with negatively charged bacterial cell components.
Electron-Donating Groups (EDGs): Methoxy (-OCH3) and amino (-NH2) groups can also be beneficial, particularly for antifungal activity, by influencing hydrogen bonding.
The N-9 Position: Alkylation at N-9 generally increases lipophilicity and membrane permeability. The nature of the alkyl chain is crucial; linear chains of moderate length (C2-C4) or chains bearing protonatable nitrogen (e.g., -CH2CH2N(Et)2) often yield the most potent compounds.
The Hybridization Approach: Linking the carbazole to another active pharmacophore often leads to synergistic effects, broadening the spectrum of activity and overcoming resistance.
Table 1: Representative examples of antimicrobial carbazole derivatives and their activities.
|
Compound Class/Structure |
Key Structural Features |
Tested Microorganisms |
MIC Range (µg/mL) |
Reference |
|
3,6-Dinitrocarbazole |
Strong EWGs at 3,6 |
S. aureus, B. subtilis |
3.12 - 6.25 |
[12] |
|
9-(2-(Diethylamino)ethyl)carbazole |
Basic aminoalkyl chain at N-9 |
S. aureus, E. coli |
12.5 - 25 |
[13] |
|
Carbazole-1,2,3-triazole Hybrid |
Triazole linker, p-OMe phenyl |
MRSA, C. albicans |
1.56 - 6.25 |
[14] |
|
Carbazole-quinolone Hybrid |
Quinolone at C-3 |
E. coli, P. aeruginosa |
0.5 - 4.0 |
[15] |
|
3,6-Dichlorocarbazole-1,4-dione |
Halogens at 3,6; dione moiety |
C. albicans |
6.25 |
[17] |
Proposed Mechanisms of Action:
While the exact mechanism for many derivatives remains under investigation, several have been proposed:
DNA Intercalation: The planar carbazole ring can insert between DNA base pairs, disrupting replication and transcription. This is a common mechanism for many tricyclic antimicrobials and anticancer agents18.
Inhibition of Topoisomerases: Some carbazole-quinolone hybrids are potent inhibitors of bacterial DNA gyrase and topoisomerase IV15.
Cell Membrane Disruption: Cationic carbazole derivatives (e.g., those with aminoalkyl chains) can act like antimicrobial peptides, disrupting the anionic bacterial cell membrane, leading to depolarization and cell death19.
Inhibition of Efflux Pumps: Certain derivatives have been shown to inhibit efflux pumps in bacteria like S. aureus, resensitizing resistant strains to conventional antibiotics20.
Inhibition of Enzymatic Activity: For antifungal azole-hybrids, the primary target is the heme-containing enzyme lanosterol 14α-demethylase.
CONCLUSION AND FUTURE PERSPECTIVES:
The carbazole nucleus has unequivocally established itself as a highly versatile and potent scaffold for the development of new antimicrobial agents. This review has highlighted the diverse synthetic approaches available for its functionalization and the compelling evidence of its efficacy against a range of bacterial and fungal pathogens, including drug-resistant strains. The SAR studies provide a clear roadmap for rational drug design, emphasizing the importance of substituent type and position.
Despite the promising in vitro data, several challenges remain on the path to clinical application. Future research should focus on:
1. In-depth Mechanistic Studies: Elucidating the precise molecular target(s) for the most promising candidates.
2. In vivo Efficacy and Toxicity: Comprehensive pharmacological studies in animal models to establish proof-of-concept, determine pharmacokinetic profiles, and assess safety.
3. Overcoming Toxicity Concerns: Some carbazole derivatives can exhibit cytotoxicity against mammalian cells, which must be carefully optimized.
4. Developing Dual-Target Agents: Designing smart hybrids that can simultaneously hit multiple microbial targets to reduce the likelihood of resistance development.
The continued exploration of the chemical space around the carbazole scaffold, guided by robust SAR and modern drug discovery principles, holds immense promise for delivering the next generation of antimicrobial therapeutics to address the urgent global challenge of AMR.
REFERENCES:
1. World Health Organization. (2021). Global action plan on antimicrobial resistance. WHO.
2. Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and Therapeutics. 2015; 40(4): 277.
3. Knölker, H. J., and Reddy, K. R. Isolation and synthesis of biologically active carbazole alkaloids. Chemical Reviews. 2002; 102(11): 4303-4427.
4. Itoigawa, M., Kashiwada, Y., Ito, C., Furukawa, H., Tachibana, Y., and Bastow, K. F. Antitumor agents 203. Carbazole alkaloid murrayaquinone A and related synthetic carbazolequinones as cytotoxic agents. Journal of Natural Products. 2000; 63(7): 893-897.
5. Schmidt, A. W., Reddy, K. R., and Knölker, H. J. Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids. Chemical Reviews. 2012; 112(6): 3193-3328.
6. Graebe, C., and Ullmann, F. Ueber die Carbazolgruppe. Justus Liebigs Annalen der Chemie. 1896; 291(1): 1-13.
7. Bischler, A., and Napieralski, B. Zur Kenntniss einer neuen Isochinolinsynthese. Berichte der deutschen chemischen Gesellschaft. 1893; 26(2): 1903-1908.
8. Cadogan, J. I. G. (). A new synthesis of carbazoles and indoles. Journal of the Chemical Society. 1962; 4253-4257.
9. Wolfe, J. P., Wagaw, S., and Buchwald, S. L. An improved catalyst system for aromatic carbon–nitrogen bond formation: the possible involvement of bis(phosphine) complexes. Journal of the American Chemical Society. 1996; 118(33): 7914-7925.
10. Miyaura, N., and Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chemical Reviews. 1995; 95(7): 2457-2483.
11. Shapiro, N. D., and Toste, F. D. A reactivity-driven approach to the discovery and development of gold-catalyzed organic reactions. Synlett. 2007; 2007(16): 2479-2484.
12. Suman, K., Bishnoi, A., and Srivastava, S. S. Synthesis and antimicrobial evaluation of some novel carbazole derivatives. Journal of Heterocyclic Chemistry. 2019; 56(4): 1425-1433.
13. Patil, S. A., Wang, J., Li, X. S., and Chen, Z. Synthesis and biological evaluation of novel carbazole amin alcohols as potential antimicrobial agents. Bioorganic and Medicinal Chemistry Letters. 2012; 22(14): 4724-4727.
14. Zhang, L., Peng, X. M., Damu, G. L., Geng, R. X., and Zhou, C. H. Comprehensive review in current developments of imidazole-based medicinal chemistry. Medicinal Research Reviews. 2014; 34(2): 340-437. (For context on hybrids).
15. Chai, X., Zhang, J., Cao, Y., Zou, Y., Wu, Q., Zhang, D., ... and Zhou, Y. Design, synthesis and molecular docking of carbazole derivatives containing an aminoguanidine moiety as potent antibacterial agents. European Journal of Medicinal Chemistry. 2017; 143: 66-74.
16. Kini, S. G., and Choudhary, S. Synthesis, antimicrobial and antioxidant activities of some new carbazole-chalcone hybrids. Medicinal Chemistry Research. 2017; 26(8): 1681-1692.
17. Kumar, D., Kumar, N. M., Chang, K. H., and Shah, K. Synthesis and anticancer activity of 5, 11-dihydro-10H-dibenzo [b, e] [1, 4] diazepin-11-one and carbazole analogs. European Journal of Medicinal Chemistry. 2010; 45(10): 4664-4668.
18. Denny, W. A. Acridine derivatives as chemotherapeutic agents. Current Medicinal Chemistry. 2002; 9(18): 1655-1665.
19. Marques, M. R., Loebenberg, R., and Almukainzi, M. Simulated biological fluids with possible application in dissolution testing. Dissolution Technologies. 2011; 18(3): 15-28.
20. Stavri, M., Piddock, L. J., and Gibbons, S. Bacterial efflux pump inhibitors from natural sources. Journal of Antimicrobial Chemotherapy. 2007; 59(6): 1247-1260.
|
Received on 17.11.2025 Revised on 06.12.2025 Accepted on 23.12.2025 Published on 31.01.2026 Available online from February 07, 2026 Asian J. Research Chem.2026; 19(1):73-76. DOI: 10.52711/0974-4150.2026.00013 ©A and V Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|